Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour

Delahunt,; Eble,; T, King; Bethwaite,; Nacey,; Thornton, Trevor

doi:10.1046/j.1365-2559.2000.00825.x

Cited by 89 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemical confirmation with mesothelial-related markers (calretinin, CK5/6 and WT-1) is helpful in the differential with nonmesothelial lesions, even in the infarcted tumors. 27,29 Electron microscopy will also help for noninfarcted lesions, but is rarely necessary.…”

Section: Reactive Mesothelial Hyperplasiamentioning

confidence: 99%

Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors

2005

View full text Add to dashboard Cite

and, in some instances, communication between several structures in the testis and paratestis (rete testis, epididymis, mesothelium, vestigial epithelium and paratesticular soft tissue) result in a plethora of interesting tumors and tumor-like lesions that together pose a formidable diagnostic challenge both because of their morphologic overlap and rarity. The occasional spread of tumors primarily at other sites to this region adds to the potential problem encountered. This review provides an overview of the pathology of nonmesenchymal paratesticular neoplasms and pseudotumors with a focus on the approach to tubulopapillary neoplasms for which diagnostic considerations may include carcinoma of the rete testis, malignant mesothelioma, ovarian-type epithelial tumors, epididymal carcinoma and metastatic carcinomas. The cornerstone of accurate characterization of these lesions is still a comprehensive, traditional clinicopathologic approach, clinical history (of another primary), gross examination (location) and routine light microscopy, but judicious incorporation of contemporary immunohistochemical markers may aid or in some instances be crucial in resolving the problems encountered. Modern Pathology (2005) 18, S131-S145.

show abstract

Section: Reactive Mesothelial Hyperplasiamentioning

confidence: 99%

Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors

2005

View full text Add to dashboard Cite

show abstract

“…Adenomatoid tumor is positive for the mesothelial markers CK5/6, calretinin, and WT1, 220,221 and negative for the epithelial markers BerEP4 and CEA. 222 Similarly, immunohistochemistry helps in differentiating FATWO, a rare tumor arising in the broad ligament, mesosalpinx, and ovary, 58 from the low-grade endometrioid adenocarcinoma variant of the fallopian tube. Unlike endometrioid adenocarcinoma, FATWO is positive for inhibin and calretinin.…”

mentioning

confidence: 99%

The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders

Kaspar

Crum

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials. Objective To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels. Data Sources Literature review and authors' personal practice experience. Conclusions The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.

show abstract

“…Cells have vesicular nuclei, small nucleoli and abundant amount of eosinophilic cytoplasm. Immunohistochemical studies show positivity for CK, EMA and calretinin but negativity for endothelial markers, supporting mesothelial derivation, [2] as do ultrastructural studies. [3] The presentation of adenomatoid tumour is unique and easily recognized by FNAC.…”

Section: Dear Sirmentioning

confidence: 57%

“…However, immunohistochemical and ultrastuctural evidence supports a mesothelial origin. [2,3] Cytological features of adenomatoid tumour have been described very briefly in literature. There are only few case reports of adenomatoid tumour of epididymis being diagnosed on cytology.…”

Section: Dear Sirmentioning

confidence: 99%

Cytology of AdenomatoidTumour of Epididymis

Singh¹,

Chaudhary²

2017

APALM

View full text Add to dashboard Cite

Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour

Abstract: The immunohistochemical profile of paratesticular adenomatoid tumour is strongly supportive of a mesothelial cell origin.

Cited by 89 publications

References 31 publications

Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors

Selected other problematic testicular and paratesticular lesions: rete testis neoplasms and pseudotumors, mesothelial lesions and secondary tumors

The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders

Cytology of AdenomatoidTumour of Epididymis

Contact Info

Product

Resources

About